Biotech Options: Trade FDA Catalysts Without IV Crush

Traders buy calls on a biotech stock two days before the PDUFA date, see the drug get approved in the morning, the stock jump 30%, and still close the day with a loss. The trade was right. The structure was wrong. They paid for the lottery ticket and won the lottery, but the ticket cost more than the prize. Here’s why biotech options work differently from every other sector, and how to use them without getting destroyed by the mechanics.

The Problem

FDA catalysts are known-in-advance binary events. Everyone knows the date. The options market prices that uncertainty into implied volatility (IV), which spikes to 200-400% in the days before a PDUFA date. When the FDA announces a decision, the uncertainty vanishes. IV collapses from 300% to 60% overnight regardless of whether the stock goes up or down. You can be right on direction and still lose money.

The Solution

Stop buying naked calls and puts ahead of PDUFA dates. Use debit spreads to neutralize IV crush, or trade the pre-PDUFA run-up and exit before the binary event. And know when to walk away entirely, because most biotech options markets are too illiquid to trade profitably.

Step 1: Understand How IV Crush Works in Biotech

IV crush is the collapse in option premiums after a binary event resolves. In biotech, it’s more extreme than in any other sector.

Here’s the math. Say a biotech stock trades at $20 with a PDUFA date two weeks away. IV on at-the-money calls is 300%. You buy a $20 call for $4.00. The implied move priced into that option is roughly a 40% stock move (the straddle price divided by the stock price). For you to break even, the stock needs to close above $24 on expiration. That’s a 20% gain, just to get your money back.

Now the FDA approves the drug. The stock opens at $26, a 30% gain. Your $20 call has $6 of intrinsic value. But IV collapsed from 300% to 60% overnight, wiping out the extrinsic premium. Your option is worth roughly $6.50, not the $10 with no IV crush. You made 62% on a call option when the stock moved 30%. Good, but not what most people expect.

Now consider the CRL scenario. The stock opens at $8, a 60% drop. Your $20 call is worthless. You lost 100%.

The options market knew the stock could move 40%. You paid for that move. If the actual move is smaller than what was priced, you lose money on a correct directional bet. This is not a quirk. It’s the defining feature of biotech options trading.

Step 2: Use Debit Spreads to Neutralize IV Crush

A debit spread buys one option and sells a further out-of-the-money option of the same type and expiration. For a PDUFA trade, buy an at-the-money call and sell a call at a higher strike.

Same example: stock at $20 before the PDUFA. Instead of buying the $20 call for $4.00, buy a $20/$25 call spread. Buy the $20 call for $4.00, sell the $25 call for $1.50. Net cost: $2.50. Max profit: $2.50 (the $5 spread width minus what you paid).

The sold $25 call also has IV crush working against it, but you’re short that option, so IV crush helps you. The spread neutralizes roughly half the vega (volatility sensitivity) of the naked call. If IV collapses by 200 percentage points, the naked call loses $2.00 in extrinsic value. The spread loses about $1.00.

The tradeoff: you cap your upside at the $25 strike. If the stock opens at $35, the naked call is worth $15 and the spread is worth $5. You left $10 on the table. But on a CRL, the naked call loses $4.00 and the spread loses $2.50. The spread costs less and protects against IV crush on both outcomes.

Step 3: Trade the Pre-PDUFA Run-Up, Not the Binary Event

Biotech stocks often rally 15-30% in the 90 days before a PDUFA date as anticipation builds and traders position for the approval. The run-up is directional, not binary, and IV is still rising but hasn’t peaked. This is the window where buying calls actually works.

Enter 60-90 days before the PDUFA date. Use calls with expiration after the PDUFA, but sell them 1-2 weeks before the decision. You’re capturing the pre-event momentum, not the event itself. You leave money on the table if the drug gets approved, but you also leave the downside on the table if it gets a CRL.

The Capricor (CAPR) AdCom in July 2026 is a textbook case. The advisory committee voted 9-3 against deramiocel for Duchenne muscular dystrophy. Anyone holding calls through the vote lost 100%. Anyone who sold calls during the pre-AdCom run-up locked in gains before the binary event.

Step 4: Understand Straddles and Why They Rarely Work

A straddle buys both a call and a put at the same strike, betting the stock will move more than the combined premium. In theory, this is perfect for a binary event: you don’t need to guess direction, just magnitude.

In practice, the options market has already priced the expected move. Pre-PDUFA IV of 300% means the market expects a 30-40% move. You need the actual move to exceed the priced move. Even on big PDUFA days, stocks often move 25-35%, which is inside the breakeven.

Straddles work when the market underestimates the binary event’s magnitude. They fail when the market prices it correctly, which is most of the time. The biotech options market is efficient. The edge isn’t being smarter. It’s knowing which setups have asymmetric risk and which don’t.

Step 5: Know When Not to Trade Options at All

This is the step most traders skip. Biotech options chains are not tradable for retail investors.

Check these three things before any biotech options trade:

Open interest. If the open interest on the strike you want is under 100 contracts, you’re trading against 3 market makers and no one else. The bid-ask spread will be 20-50% of the option price. You’re down 20% before the trade even starts.

Bid-ask spread. On small-cap biotechs ($100M-$500M market cap), options spreads can be $0.50 wide on a $1.50 option. That’s a 33% spread. You need a 33% edge just to break even. On large-cap names like Gilead (GILD) or Merck (MRK), spreads narrow to pennies. Trade where you have a fair market.

Market cap. Options on biotechs valued below $500 million are almost never liquid enough to trade. Even $1-2 billion market cap names can have wide spreads. The sweet spot for biotech options is $2-10 billion market cap with a major catalyst approaching.

The Celcuity (CELC) Revtorpyk approval in July 2026 illustrates the post-approval fade risk. The stock was approved, popped, and then faded over the following weeks as traders sold the news. Call holders who didn’t exit immediately watched their profits evaporate despite being right on the catalyst.

Common Mistakes

Buying naked calls the day before a PDUFA date. IV has peaked. You’re paying maximum premium for maximum uncertainty. Even on approval, the stock needs to exceed the implied move for you to profit. On a CRL, you lose everything.

Ignoring bid-ask spreads on small-cap options. A $0.50 spread on a $2.00 option means the stock needs to move an additional 25% just to cover the spread. Most small-cap biotech options are not tradable at any price that makes mathematical sense.

Holding options through the binary event when you have a profit on the run-up. If your calls are up 40% a week before the PDUFA date, sell. You’ve captured the pre-event move. The remaining 40% approval pop isn’t worth the 100% CRL risk.

Using more than 2-3% of your portfolio on any biotech options trade. You will be wrong sometimes. With options, being wrong means losing 50-100% of the position. Size accordingly.

Final Checklist

• Check open interest: at least 100 contracts at your strike
• Check bid-ask spread: less than 5% of the option price
• Use debit spreads, not naked calls, if holding through the PDUFA date
• Consider selling during the pre-PDUFA run-up instead of holding through the binary event
• Never risk more than 2-3% of your portfolio on a single biotech options trade
• Skip options entirely on stocks below $500 million market cap

For the stock-side framework on trading FDA catalysts, start with the FDA catalyst trading guide. For the regulatory mechanics behind CRLs and how to evaluate the risk before you trade, read the Capricor deramiocel AdCom analysis. If you’re building a full biotech portfolio and want to know how options positions fit into your allocation, see the biotech portfolio construction guide. Find upcoming PDUFA dates and catalyst information at BioPharmCatalyst.